227 related articles for article (PubMed ID: 31413354)
41. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial.
Klaver CEL; Wisselink DD; Punt CJA; Snaebjornsson P; Crezee J; Aalbers AGJ; Brandt A; Bremers AJA; Burger JWA; Fabry HFJ; Ferenschild F; Festen S; van Grevenstein WMU; Hemmer PHJ; de Hingh IHJT; Kok NFM; Musters GD; Schoonderwoerd L; Tuynman JB; van de Ven AWH; van Westreenen HL; Wiezer MJ; Zimmerman DDE; van Zweeden AA; Dijkgraaf MGW; Tanis PJ;
Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):761-770. PubMed ID: 31371228
[TBL] [Abstract][Full Text] [Related]
42. Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study.
Gao P; Huang XZ; Song YX; Sun JX; Chen XW; Sun Y; Jiang YM; Wang ZN
BMC Cancer; 2018 Mar; 18(1):234. PubMed ID: 29490625
[TBL] [Abstract][Full Text] [Related]
43. Reduced risk of distant recurrence after adjuvant chemotherapy in patients with stage III colon cancer aged 75 years or older.
van Erning FN; Creemers GJ; De Hingh IH; Loosveld OJ; Goey SH; Lemmens VE
Ann Oncol; 2013 Nov; 24(11):2839-44. PubMed ID: 23933560
[TBL] [Abstract][Full Text] [Related]
44. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
[TBL] [Abstract][Full Text] [Related]
45. Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Colon Cancer in Elderly Patients: A Propensity Score Analysis.
Mazaki J; Katsumata K; Sujino H; Udo R; Tago T; Kasahara K; Kuwabara H; Enomoto M; Ishizaki T; Nagakawa Y; Tsuchida A
Anticancer Res; 2021 Sep; 41(9):4471-4478. PubMed ID: 34475071
[TBL] [Abstract][Full Text] [Related]
46. Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study.
Baretti M; Rimassa L; Personeni N; Giordano L; Tronconi MC; Pressiani T; Bozzarelli S; Santoro A
Clin Colorectal Cancer; 2018 Sep; 17(3):e489-e498. PubMed ID: 29650416
[TBL] [Abstract][Full Text] [Related]
47. Benefit of Postresection Adjuvant Chemotherapy for Stage III Colon Cancer in Octogenarians: Analysis of the National Cancer Database.
Bergquist JR; Thiels CA; Spindler BA; Shubert CR; Hayman AV; Kelley SR; Larson DW; Habermann EB; Pemberton JH; Mathis KL
Dis Colon Rectum; 2016 Dec; 59(12):1142-1149. PubMed ID: 27824699
[TBL] [Abstract][Full Text] [Related]
48. Real-world analysis of survival benefit of surgery and adjuvant therapy in elderly patients with colorectal cancer.
Zhang L; Li Q; Hu C; Zhang Z; She J; Shi F
Sci Rep; 2023 Sep; 13(1):14866. PubMed ID: 37684265
[TBL] [Abstract][Full Text] [Related]
49. Relationship Between Metformin Use and Recurrence and Survival in Patients With Resected Stage III Colon Cancer Receiving Adjuvant Chemotherapy: Results From North Central Cancer Treatment Group N0147 (Alliance).
Singh PP; Shi Q; Foster NR; Grothey A; Nair SG; Chan E; Shields AF; Goldberg RM; Gill S; Kahlenberg MS; Sinicrope FA; Sargent DJ; Alberts SR
Oncologist; 2016 Dec; 21(12):1509-1521. PubMed ID: 27881709
[TBL] [Abstract][Full Text] [Related]
50. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
Yun HR; Kim HC; Yun SH; Lee WY
Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
[TBL] [Abstract][Full Text] [Related]
51. Safety and efficacy of a modified XELOX adjuvant regimen for patients with operated stage III colon cancer: a Chinese single-center experience.
Peng J; Li W; Zhang R; Lin J; Tang J; Wen Y; Lu Z; Wu X; Pan Z
Cancer Commun (Lond); 2019 Oct; 39(1):59. PubMed ID: 31619288
[TBL] [Abstract][Full Text] [Related]
52. Adjuvant chemotherapy benefits on patients with elevated carcinoembryonic antigen in stage IIA colon cancer: a SEER-based analysis.
Zhou H; Wang S; Cai Z; Qiu E; Chen Q; Rao X; Han S; Li Z
Int J Colorectal Dis; 2022 Dec; 37(12):2481-2489. PubMed ID: 36334109
[TBL] [Abstract][Full Text] [Related]
53. Use of adjuvant chemotherapy in patients with stage III colon cancer in Puerto Rico: A population-based study.
Ortiz-Ortiz KJ; Tortolero-Luna G; Ríos-Motta R; Veintidós-Feliú A; Hunter-Mellado R; Torres-Cintrón CR; Suárez-Ramos T; Magno P
PLoS One; 2018; 13(3):e0194415. PubMed ID: 29584752
[TBL] [Abstract][Full Text] [Related]
54. Clinical consequences of chemotherapy dose reduction in obese patients with stage III colon cancer: A retrospective analysis from the PETACC 3 study.
Stocker G; Hacker UT; Fiteni F; John Mahachie J; Roth AD; Van Cutsem E; Peeters M; Lordick F; Mauer M
Eur J Cancer; 2018 Aug; 99():49-57. PubMed ID: 29906734
[TBL] [Abstract][Full Text] [Related]
55. Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011.
Zhao H; Zhang N; Ho V; Ding M; He W; Niu J; Yang M; Du XL; Zorzi D; Chavez-MacGregor M; Giordano SH
Cancer; 2018 Feb; 124(4):679-687. PubMed ID: 29140558
[TBL] [Abstract][Full Text] [Related]
56. Efficacy of adjuvant chemotherapy for small bowel adenocarcinoma: A propensity score-matched analysis.
Ecker BL; McMillan MT; Datta J; Mamtani R; Giantonio BJ; Dempsey DT; Fraker DL; Drebin JA; Karakousis GC; Roses RE
Cancer; 2016 Mar; 122(5):693-701. PubMed ID: 26717303
[TBL] [Abstract][Full Text] [Related]
57. Prognostic Implications of Endoscopic Obstruction in Patients with Pathological Stage II Colon Cancers: a Single-Center Retrospective Cohort Study.
Mo TW; Zhang ZJ; Shi YQ; Xiang HD; Chen YL; Chen ZX; Hu JC; He XW
J Gastrointest Surg; 2023 Jan; 27(1):141-151. PubMed ID: 36352061
[TBL] [Abstract][Full Text] [Related]
58. Propensity-matched analysis of adjuvant chemotherapy for completely resected Stage IB non-small-cell lung cancer patients.
Li X; Zhang C; Sun Z; Yang F; Xiao R; Sui X; Jiang G; Zhong W; Wang J
Lung Cancer; 2019 Jul; 133():75-82. PubMed ID: 31200832
[TBL] [Abstract][Full Text] [Related]
59. Propensity-Score Matched Analysis of Survival Outcomes of Adjuvant Therapy in Stage II-III Signet-Ring Cell Carcinoma of the Colon.
Emile SH; Horesh N; Garoufalia Z; Gefen R; Strassmann V; Wexner SD
Clin Colorectal Cancer; 2024 Mar; 23(1):35-45. PubMed ID: 37980215
[TBL] [Abstract][Full Text] [Related]
60. Prognostic and predictive value of a microRNA signature in stage II colon cancer: a microRNA expression analysis.
Zhang JX; Song W; Chen ZH; Wei JH; Liao YJ; Lei J; Hu M; Chen GZ; Liao B; Lu J; Zhao HW; Chen W; He YL; Wang HY; Xie D; Luo JH
Lancet Oncol; 2013 Dec; 14(13):1295-306. PubMed ID: 24239208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
